JP2017511305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511305A5 JP2017511305A5 JP2016556997A JP2016556997A JP2017511305A5 JP 2017511305 A5 JP2017511305 A5 JP 2017511305A5 JP 2016556997 A JP2016556997 A JP 2016556997A JP 2016556997 A JP2016556997 A JP 2016556997A JP 2017511305 A5 JP2017511305 A5 JP 2017511305A5
- Authority
- JP
- Japan
- Prior art keywords
- bond
- substituted
- unsubstituted
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 85
- 125000003118 aryl group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 77
- 125000001072 heteroaryl group Chemical group 0.000 claims description 72
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 51
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 48
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 48
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 43
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 43
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 125000000304 alkynyl group Chemical group 0.000 claims description 42
- 239000012190 activator Substances 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 125000004450 alkenylene group Chemical group 0.000 claims description 32
- 125000004419 alkynylene group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 229940124530 sulfonamide Drugs 0.000 claims description 13
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 6
- 125000005587 carbonate group Chemical group 0.000 claims description 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 6
- 125000004185 ester group Chemical group 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 6
- 150000007970 thio esters Chemical group 0.000 claims description 6
- -1 thioacid group Chemical group 0.000 claims description 6
- 125000000101 thioether group Chemical group 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- BEHLMOQXOSLGHN-UHFFFAOYSA-N benzenamine sulfate Chemical group OS(=O)(=O)NC1=CC=CC=C1 BEHLMOQXOSLGHN-UHFFFAOYSA-N 0.000 claims 7
- PXFORDPOPVGNJL-UHFFFAOYSA-N diphenylsulfamic acid Chemical class C=1C=CC=CC=1N(S(=O)(=O)O)C1=CC=CC=C1 PXFORDPOPVGNJL-UHFFFAOYSA-N 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 0 COC(N[C@@](C(N[C@@](Cc(cc1)ccc1NS(*)(=*)=O)c1c[s]c(-c2ccc[s]2)n1)=O)N=Cc1ccccc1)=* Chemical compound COC(N[C@@](C(N[C@@](Cc(cc1)ccc1NS(*)(=*)=O)c1c[s]c(-c2ccc[s]2)n1)=O)N=Cc1ccccc1)=* 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953680P | 2014-03-14 | 2014-03-14 | |
| US61/953,680 | 2014-03-14 | ||
| PCT/US2015/020425 WO2015138882A1 (en) | 2014-03-14 | 2015-03-13 | Hptp-beta inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246712A Division JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511305A JP2017511305A (ja) | 2017-04-20 |
| JP2017511305A5 true JP2017511305A5 (cg-RX-API-DMAC7.html) | 2018-04-12 |
| JP6483148B2 JP6483148B2 (ja) | 2019-03-13 |
Family
ID=54068203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556997A Active JP6483148B2 (ja) | 2014-03-14 | 2015-03-13 | ＨＰＴＰ−β阻害剤 |
| JP2018246712A Active JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
| JP2019077696A Withdrawn JP2019108407A (ja) | 2014-03-14 | 2019-04-16 | ＨＰＴＰ−β阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246712A Active JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
| JP2019077696A Withdrawn JP2019108407A (ja) | 2014-03-14 | 2019-04-16 | ＨＰＴＰ−β阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9994560B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3116503A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6483148B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456614A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015138882A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| DK2385763T3 (en) * | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9440963B2 (en) | 2013-03-15 | 2016-09-13 | Aerpio Therapeutics, Inc. | Compositions, formulations and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| EP3977994B1 (en) * | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| US20190262321A1 (en) * | 2018-02-26 | 2019-08-29 | Aerpio Therapeutics, Inc. | Methods of treating diabetic nephropathy using hptpb inhibitors |
| US20210283051A1 (en) * | 2018-07-13 | 2021-09-16 | Mannin Research, Inc. | Ve-ptp inhibition in glaucoma |
| CN119462635A (zh) | 2018-10-30 | 2025-02-18 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| CA3137138A1 (en) * | 2019-04-18 | 2020-10-22 | EyePoint Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
| EP3962482A4 (en) * | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
| KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| US11613534B2 (en) | 2019-10-29 | 2023-03-28 | EyePoint Pharmaceuticals, Inc. | Small molecule activators of Tie-2 |
| CN113060789A (zh) * | 2019-12-31 | 2021-07-02 | 大连乾丰生物科技有限公司 | 一种海蜇池塘水底质改良剂 |
| CA3202338A1 (en) * | 2020-12-18 | 2022-06-23 | EyePoint Pharmaceuticals, Inc. | Methods for manufacture of small molecule activators of tie-2 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221584A (en) | 1979-02-09 | 1980-09-09 | Chevron Research Company | Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides |
| US4735961A (en) * | 1984-05-07 | 1988-04-05 | Merck & Co., Inc. | Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety |
| AR003108A1 (es) * | 1995-01-27 | 1998-07-08 | Novo Nordisk As | Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento. |
| JP4122056B2 (ja) | 1995-04-06 | 2008-07-23 | リジエネロン ファーマシューティカルズ，インコーポレイテッド | Ｔｉｅ−２リガンド、その作製方法および使用方法 |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| EP1165115B1 (en) | 1999-03-26 | 2003-05-28 | Regeneron Pharmaceuticals, Inc. | Modulation of vascular permeability by mean of tie2 receptor activators |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| KR20080068151A (ko) | 2000-06-23 | 2008-07-22 | 바이엘 쉐링 파마 악티엔게젤샤프트 | ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
| AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| DE60315603T2 (de) | 2002-02-25 | 2008-05-21 | Eli Lilly And Co., Indianapolis | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
| WO2003084565A2 (en) | 2002-04-08 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| AU2003231098A1 (en) | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| LT2653465T (lt) | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| US20070208068A1 (en) * | 2004-03-18 | 2007-09-06 | R-Tech Ueno, Ltd. & Astellas Pharma Inc. | Aqueous Composition Comprising Thiazole Derivative |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| DK2457578T3 (en) | 2004-09-28 | 2015-12-07 | Aprogen Inc | A chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in the treatment of erectile dysfunction of the penis |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8957022B2 (en) | 2006-10-27 | 2015-02-17 | Sunnybrook Health Sciences Centre | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| DK2385763T3 (en) | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| EP2403342A4 (en) | 2009-03-03 | 2013-06-05 | Alcon Res Ltd | PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI) |
| CA2753690A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| PH12012500788A1 (en) | 2009-11-06 | 2016-07-27 | Aerpio Therapeutics Inc | Compositions and methods for treating colitis |
| US20110319455A1 (en) | 2010-04-19 | 2011-12-29 | Bruce Steven Klein | Antifungal Treatment |
| MX2012014428A (es) | 2010-07-12 | 2013-03-05 | Threshold Pharmaceuticals Inc | Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer. |
| CA2818215C (en) | 2010-10-07 | 2015-07-21 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| EP2857032A3 (en) | 2010-12-02 | 2015-07-15 | Maruzen Pharmaceuticals Co., Ltd. | Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| BR112014008759A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Tratamento de doença ocular |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| AU2013245630A1 (en) | 2012-04-13 | 2014-10-30 | The Johns Hopkins University | Treatment of ischemic retinopathies |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| LT2880167T (lt) | 2012-07-31 | 2018-10-25 | The Board Of Regents Of The University Of Texas System | Kasos beta-ląstelių in vivo indukcijos būdai ir kompozicijos |
| CN104755103A (zh) | 2012-10-11 | 2015-07-01 | 阿森迪斯药物眼科部股份有限公司 | 用于治疗眼病症的中和vegf的前药 |
| BR112015010566A2 (pt) | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
| WO2014079709A1 (en) | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9440963B2 (en) | 2013-03-15 | 2016-09-13 | Aerpio Therapeutics, Inc. | Compositions, formulations and methods for treating ocular diseases |
| US10314882B2 (en) | 2013-04-11 | 2019-06-11 | Sunnybrook Research Institute | Methods, uses and compositions of Tie2 agonists |
| US20160130321A1 (en) | 2013-06-20 | 2016-05-12 | Gabriela Burian | Use of a vegf antagonist in treating macular edema |
| EP3010525A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating choroidal neovascularisation |
| WO2015002893A1 (en) | 2013-07-02 | 2015-01-08 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| RU2676303C2 (ru) | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| EP3019526A1 (en) | 2013-07-11 | 2016-05-18 | Novartis AG | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| JP6419794B2 (ja) | 2013-10-01 | 2018-11-07 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 主要な心臓有害事象に罹患する危険性を予測する方法 |
| ES2727532T3 (es) | 2013-11-01 | 2019-10-16 | Regeneron Pharma | Intervenciones basadas en angiopoyetina para el tratamiento de la malaria cerebral |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| JP2015199733A (ja) | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2015
- 2015-03-13 EP EP15760687.2A patent/EP3116503A4/en not_active Withdrawn
- 2015-03-13 WO PCT/US2015/020425 patent/WO2015138882A1/en not_active Ceased
- 2015-03-13 US US14/657,276 patent/US9994560B2/en active Active
- 2015-03-13 JP JP2016556997A patent/JP6483148B2/ja active Active
- 2015-03-13 CN CN201580026210.0A patent/CN106456614A/zh active Pending
-
2018
- 2018-05-07 US US15/972,863 patent/US10858354B2/en active Active
- 2018-12-28 JP JP2018246712A patent/JP6661744B2/ja active Active
-
2019
- 2019-04-16 JP JP2019077696A patent/JP2019108407A/ja not_active Withdrawn
-
2020
- 2020-10-02 US US17/062,098 patent/US20210130341A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511305A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515776A5 (cg-RX-API-DMAC7.html) | ||
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| JP2008509166A5 (cg-RX-API-DMAC7.html) | ||
| CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
| JP2017535555A5 (cg-RX-API-DMAC7.html) | ||
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR093047A1 (es) | Compuestos heterociclicos nitrogenados | |
| An et al. | Copper‐Mediated Halotrifluoromethylation of Unactivated Alkenes | |
| JP2015535839A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528273A5 (cg-RX-API-DMAC7.html) | ||
| EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
| JP2018530582A5 (cg-RX-API-DMAC7.html) | ||
| JP2017519796A5 (cg-RX-API-DMAC7.html) | ||
| JP2006523626A5 (cg-RX-API-DMAC7.html) | ||
| ATE441627T1 (de) | Verfahren zur herstellung von valsartan | |
| EA201200726A1 (ru) | Способ синтеза, кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат | |
| RU2013140467A (ru) | Выделенные соединения из масла куркумы и способы применения | |
| JP2018501266A5 (cg-RX-API-DMAC7.html) | ||
| RU2012136457A (ru) | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) | |
| JP2018536637A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513885A5 (cg-RX-API-DMAC7.html) | ||
| JP2010538023A5 (cg-RX-API-DMAC7.html) |